Results 41 to 50 of about 5,422 (196)

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report

Pediatric Hematology Oncology Journal
Background: Mitotane is employed as adjuvant therapy in managing adrenocortical carcinoma in pediatric patients. While various adverse effects, such as estrogen-like manifestations, are well-documented in adults, there is limited knowledge regarding ...
Maria Riedmeier, Sonir Antonini, Clemens Benoit, Cheri L. Deal, Fassnacht Martin, Bonald C. Figueiredo, Elmas Nazli Gonc, Christoph Härtel, Jan Idkowiak, Max Kurlbaum, Ronald de Krijger, Raul C. Ribeiro, Jaydira del Rivero, Paul-Gerhardt Schlegel, Lester D.R. Thompson, Bilgehan Yalcin, Verena Wiegering   +16 more
doaj   +1 more source

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor

Endocrinology, Diabetes & Metabolism Case Reports, 2018
Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane,
Philip D Oddie, Benjamin B Albert, Paul L Hofman, Craig Jefferies, Stephen Laughton, Philippa J Carter   +5 more
doaj   +1 more source

Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice

Clinical Endocrinology, Volume 104, Issue 3, Page 215-221, March 2026.
ABSTRACT Objective Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase inhibitor, it has been shown that it is possible to reset the abnormal circadian cortisol rhythm in MACS ...
Simon Berry, Ahmed Iqbal, John Newell‐Price, Miguel Debono   +3 more
wiley   +1 more source

Clinical results of the use of mitotane for adrenocortical carcinoma

Brazilian Journal of Medical and Biological Research, 2000
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synthesis. Its adrenolytic effect depends on metabolic activation due to conversion to o,p'-DDA and o,p'-DDE.
A.A. Kasperlik-Zaluska
doaj   +1 more source

Corticotropinoma as a Component of Carney Complex. [PDF]

, 2017
Known germline gene abnormalities cause one-fifth of the pituitary adenomas in children and adolescents, but, in contrast with other pituitary tumor types, the genetic causes of corticotropinomas are largely unknown.
Chittiboina, Prashant, Dimopoulos, Aggeliki, Faucz, Fabio R, Hernández-Ramírez, Laura C, Kay, Denise M, Lane, John, Lodish, Maya B, Mills, James L, Pankratz, Nathan, Stratakis, Constantine A, Tatsi, Christina, Valdés, Nuria   +11 more
core   +2 more sources

Mitotane (op’DDD) restores growth and puberty in nine children with Cushing’s disease

Endocrine Connections, 2018
To investigate whether low-dose mitotane (up to 2 g/day) could be a temporary therapeutic alternative to transsphenoidal surgery (TSS) in pediatric Cushing’s disease (CD). Twenty-eight patients with CD aged 12.2 years (± 2.2) were referred to our center.
Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant, Agnès Linglart   +6 more
doaj   +1 more source

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog

Veterinary Medicine and Science, 2021
Background Occult (or atypical) hyperadrenocorticism (HAC) shows clinical signs and laboratory abnormalities similar to classic hyperadrenocorticism, but normal signs in routine screening tests such as the corticotropin (ACTH) stimulation test and low ...
Su‐Min Park, Kyeong‐Bo Kim, Woo‐Jin Song, Hwa‐Young Youn   +3 more
doaj   +1 more source

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers

Frontiers in Oncology, 2021
Mitotane has been used for the treatment of adrenocortical cancer (ACC) for over 50 years. Despite its widespread use both in monotherapy and in combination with chemotherapeutics, our knowledge of its mechanism of action and therapeutic efficacy is ...
Judit Tőke, Zsuzsanna Jakab, Júlia Stark, Gergely Huszty, Péter Reismann, Miklós Tóth   +5 more
doaj   +1 more source

Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line

Pharmaceuticals, 2022
In South Brazil, the incidence of pediatric adrenocortical carcinoma (ACC) is higher than in other regions and countries worldwide. The ACC treatment includes therapy with mitotane, the only adrenolytic drug approved by the FDA.
Camila Bach, Claudia Rita Corso, Alan de Almeida Veiga, Mariana Martins Paraizo, Lauro Mera de Souza   +4 more
doaj   +1 more source

Effective treatment with mitotane for a canine case of Ectopic Cushing's syndrome-related pheochromocytoma.

Open Veterinary Journal, 2022
In humans, ectopic Cushing's syndrome (ECS) is characterized by hypercortisolemia, which is caused by small lung carcinoma, bronchial carcinoids, and pheochromocytoma.
Konatsu Miura, Hiroshi Sunahara, Yusuke Sakai   +2 more
doaj   +1 more source